Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8153223 | 0.87 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1EPHX2EPHX1NPY5R | |
| SCHEMBL1196740 | 0.87 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1EPHX2EPHX1NPY5R | |
| SCHEMBL8159119 | 0.87 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1EPHX2EPHX1NPY5R | |
| SCHEMBL22878132 | 0.84 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1NPY5RSMN1; SMN2 | |
| SCHEMBL14997483 | 0.84 | EPHX2 (0.43) | L3MBTL3CYP1A2TDP1EPHX2EPHX1 | |
| SCHEMBL19710577 | 0.84 | KDM4E (0.45) | L3MBTL3L3MBTL1CYP1A2TDP1EPHX2 | |
| SCHEMBL27781047 | 0.84 | L3MBTL3 (0.60) | L3MBTL3L3MBTL1 | |
| SCHEMBL13803962 | 0.83 | NPY5R (0.47) | L3MBTL3L3MBTL1CYP1A2TDP1EPHX2 | |
| SCHEMBL220870 | 0.83 | EPHX2 (0.42) | L3MBTL3CYP1A2TDP1EPHX2EPHX1 | |
| SCHEMBL20002211 | 0.83 | EPHX2 (0.42) | L3MBTL3CYP1A2TDP1EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545668-B2 | Cyclic amine derivative as agent for promoting advillin function, and novel cyclic amine derivative and pharmaceutical use thereof | TORAY INDUSTRIES, INC. (JP) | 2026-02-10 | — | — | US | disclosed |
| EP-3777858-B1 | AGENT FOR INHIBITING RISE IN INTRANEURONAL CALCIUM CONCENTRATION | TORAY INDUSTRIES (JP) | 2025-04-02 | — | — | EP | disclosed |
| WO-2024129948-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF S1P5 | CELGENE CORPORATION (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024020458-A1 | METHOD OF TREATING ORGAN DISEASES OR DISORDERS WITH ASK1 INHIBITORS | Seal Rock Therapeutics, Inc. (US) | 2024-01-25 | — | — | WO | disclosed |
| CN-111902143-B | Inhibitors of calcium concentration increase in nerve cells | 东丽株式会社 | 2024-01-02 | — | — | CN | disclosed |
| US-11834431-B2 | Crystals of cyclic amine derivative and pharmaceutical use thereof | TORAY INDUSTRIES, INC. (JP) | 2023-12-05 | — | — | US | disclosed |
| US-11834431-B2 | Crystals of cyclic amine derivative and pharmaceutical use thereof | TORAY INDUSTRIES, INC. (JP) | 2023-12-05 | — | — | US | disclosed |
| US-11834431-B2 | Crystals of cyclic amine derivative and pharmaceutical use thereof | TORAY INDUSTRIES, INC. (JP) | 2023-12-05 | — | — | US | disclosed |
| US-20230248740-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | NATIONAL CANCER CENTER (KR) | 2023-08-10 | — | — | US | disclosed |
| US-20230248740-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | NATIONAL CANCER CENTER (KR) | 2023-08-10 | — | — | US | disclosed |
| WO-2009026276-A1 | 5- (4- (HALOALKOXY) PHENYL) PYRIMIDINE-2-AMINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009026204-A1 | 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2009-02-26 | — | — | WO | disclosed |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008124848-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-07-31 | — | — | US | disclosed |
| US-20070203184-A1 | Novel Indolin-2-one Derivatives, Their Preparation and the Pharmaceutical Compositions Comprising Them | SANOFI-AVENTIS (FR) | 2007-08-30 | — | — | US | disclosed |
| US-20070203184-A1 | Novel Indolin-2-one Derivatives, Their Preparation and the Pharmaceutical Compositions Comprising Them | SANOFI-AVENTIS (FR) | 2007-08-30 | — | — | US | disclosed |
| US-7160877-B2 | Aliphatic nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545668-B2 | Cyclic amine derivative as agent for promoting advillin function, and novel cyclic amine derivative and pharmaceutical use thereof | SSB, TLR9, C5AR2 | L3MBTL3 4333/4885L3MBTL1 4096/4885CYP1A2 4411/4885 |
| US-20070203184-A1 | Novel Indolin-2-one Derivatives, Their Preparation and the Pharmaceutical Compositions Comprising Them | OXTR, AVPR2, AVPR1B | L3MBTL3 4880/4885L3MBTL1 4873/4885CYP1A2 1330/4885 |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | ADORA2A, ADORA1, ADORA3 | L3MBTL3 4688/4885L3MBTL1 4612/4885CYP1A2 497/4885 |
| US-11834431-B2 | Crystals of cyclic amine derivative and pharmaceutical use thereof | HTR1D, HTR1A, HTR1B | L3MBTL3 4699/4885L3MBTL1 4610/4885CYP1A2 390/4885 |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, MAP3K19, MAP4K2 | L3MBTL3 3116/4885L3MBTL1 2774/4885CYP1A2 3975/4885 |
| US-20230248740-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | LRRK2, FABP7, PARK7 | L3MBTL3 1291/4885L3MBTL1 883/4885CYP1A2 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.